Related Experiment Video
Updated: Aug 8, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload
Stephen C Nelson1, Jane M Hennessy, Elizabeth A McDonough
1Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA. stephen.nelson@childrensmn.org
Insights
High-dose intravenous deferoxamine effectively manages iron overload in children needing frequent transfusions. This outpatient treatment is safe, practical, and well-tolerated, improving patient outcomes.
Area of Science:
- Pediatric Hematology
- Clinical Pharmacology
Background:
- Iron overload is a significant complication for pediatric patients requiring chronic red blood cell transfusions.
- Subcutaneous deferoxamine administration often faces challenges with patient compliance.
Purpose of the Study:
- To evaluate the safety and efficacy of a very high-dose intravenous deferoxamine regimen in pediatric patients with iron overload.
- To assess the practicality and tolerability of this intensive treatment protocol.
Main Methods:
- Fourteen pediatric patients received intravenous deferoxamine at a high dose (15 mg/kg/h) over 48 hours, administered every 2 or 4 weeks.
- The treatment duration averaged 18 months.
- Outpatient administration without central venous catheter use was employed.
Main Results:
- The intermittent very high-dose intravenous deferoxamine regimen was well-tolerated by the pediatric patients.
- The treatment proved successful in effectively removing excess iron from the body.
- The regimen was practical for outpatient administration.
Conclusions:
- Intermittent very high-dose intravenous deferoxamine is a safe, practical, and effective strategy for managing iron overload in children.
- This treatment approach offers a viable alternative for pediatric patients with transfusion-dependent anemias, improving compliance and iron chelation outcomes.
Abstract:
Iron overload can be a major complication in children requiring chronic red cell transfusions. Compliance with subcutaneous deferoxamine is often poor. We report the use of very high-dose deferoxamine in 14 children. Patients received intravenous deferoxamine at 15 mg/kg/h over 48 hours every 2 or 4 weeks. The mean duration of treatment was 18 months. Therapy was well tolerated and our regimen was successful in removing excess iron. Intermittent very high-dose intravenous deferoxamine is practical, safe, and effective in managing iron overload in children. Treatment can be given as an outpatient without a central venous catheter.
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Effects of EDTA on End-Point Detection Methods
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a result, EDTA...
